Next generation sequencing (NGS) of the MDS revealed somatic DNMT3A, TET2 and ZRSR2 mutations, and the patient was referred for germline cancer risk testing given his personal and family history of MDS/AML. This evidence concerns the gene DNMT3A and myelodysplastic syndrome.